^
Association details:
| Biomarker: | NF1 mutation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug Class: | MEK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SYSTEMATIC IDENTIFICATION OF PHARMACOGENOMICS INTERACTIONS MODULATING DRUG RESPONSES IN MULTIPLE MYELOMA
Published date:
05/17/2018
Excerpt:
101 bone marrow (BM) aspirates were collected from 32 newly diagnosed and 51 relapsed myeloma patients...MEK inhibitor response was detected in 55% of samples with NRAS, KRAS, NF1, and BRAF mutations.
